儿童和青少年抑郁症与自杀风险筛查:美国预防服务工作组推荐声明
美国预防服务工作组(USPSTF)基于系统综述更新2014和2016年推荐,评估初级保健中筛查与治疗儿童青少年重性抑郁障碍(MDD)及自杀风险的利弊。工作组得出中等确定性结论:筛查12至18岁青少年MDD有中等净获益(B推荐);对11岁及以下儿童MDD筛查及儿童青少年自杀风险筛查,证据不足以评估利弊平衡(I声明)。
要点
- USPSTF推荐对12至18岁青少年筛查MDD(B推荐)。
- 对11岁及以下儿童筛查MDD,证据不足以评估利弊平衡(I声明)。
- 对儿童青少年筛查自杀风险,证据不足以评估利弊平衡(I声明)。
核心结论
- USPSTF得出中等确定性结论:筛查12至18岁青少年MDD有中等净获益。
- USPSTF认为证据不足以评估11岁及以下儿童MDD筛查的利弊平衡。
- USPSTF认为因缺乏证据,不足以评估儿童青少年自杀风险筛查的利弊平衡。
研究设计与样本
- USPSTF委托系统综述评估筛查利弊、筛查准确性及治疗利弊,适用于初级保健场景。
- 目标人群为未诊断精神健康状况或未显示抑郁或自杀风险公认体征或症状的儿童和青少年。
- 本推荐声明更新USPSTF 2014年和2016年推荐。
主要发现
- USPSTF得出中等确定性结论:筛查12至18岁青少年MDD有中等净获益。
- USPSTF认为证据不足以评估11岁及以下儿童MDD筛查的利弊平衡。
- USPSTF认为因缺乏证据,不足以评估儿童青少年自杀风险筛查的利弊平衡。
关键数值与推荐
- USPSTF推荐对12至18岁青少年筛查MDD(B推荐)。
- USPSTF认为当前证据不足以评估11岁及以下儿童MDD筛查的利弊平衡(I声明)。
- USPSTF认为当前证据不足以评估儿童青少年自杀风险筛查的利弊平衡(I声明)。
临床怎么用
- 原文未据此给出具体临床操作推荐。
局限性
- USPSTF认为因缺乏证据,不足以评估儿童青少年自杀风险筛查的利弊平衡。
- USPSTF认为证据不足以评估11岁及以下儿童MDD筛查的利弊平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Depression is a leading cause of disability in the US. Children and adolescents with depression typically have functional impairments in their performance at school or work as well as in their interactions with their families and peers. Depression can also negatively affect the developmental trajectories of affected youth. Major depressive disorder (MDD) in children and adolescents is strongly associated with recurrent depression in adulthood; other mental disorders; and increased risk for suicidal ideation, suicide attempts, and suicide completion. Suicide is the second-leading cause of death among youth aged 10 to 19 years. Psychiatric disorders and previous suicide attempts increase suicide risk. OBJECTIVE: To update its 2014 and 2016 recommendations, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening, accuracy of screening, and benefits and harms of treatment of MDD and suicide risk in children and adolescents that would be applicable to primary care settings. POPULATION: Children and adolescents who do not have a diagnosed mental health condition or are not showing recognized signs or symptoms of depression or suicide risk. EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that screening for MDD in adolescents aged 12 to 18 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient on screening for MDD in children 11 years or younger. The USPSTF concludes that the evidence is insufficient on the benefit and harms of screening for suicide risk in children and adolescents owing to a lack of evidence. RECOMMENDATION: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children 11 years or younger. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for suicide risk in children and adolescents. (I statement).
引用
- Mangione CM, Barry MJ, Nicholson WK, et al. Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2022. PMID: 36219440. doi:10.1001/jama.2022.16946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。